BACKGROUND: It is unclear whether the disproportionately higher incidence and mortality from colorectal cancer among blacks compared with whites reflect differences in health-care utilization or colorectal cancer susceptibility. METHODS: A total of 60, 572 non-Hispanic white and black participants in the ongoing Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial underwent trial-sponsored screening flexible sigmoidoscopy (FSG) without biopsy at baseline in 10 geographically dispersed centers from November 1993 to July 2001. Subjects with polyps or mass lesions detected by FSG were referred to their physicians for diagnostic workup, the cost of which was not covered by PLCO. The records of follow-up evaluations were collected and reviewed. We used log binomial modeling with adjustment for age, education, sex, body mass index, smoking, family history of colorectal cancer, colon examination within previous 3 years, personal history of polyps, and screening center to examine whether utilization of diagnostic colonoscopy and yield of neoplasia differed by race. RESULTS: Among 57 561 whites and 3011 blacks who underwent FSG, 13,743 (23.9%) and 767 (25.5%) had abnormal examinations, respectively. A total of 9944 (72.4%) whites and 480 (62.6%) blacks had diagnostic colonoscopy within 1 year following the abnormal FSG screening. When compared with whites, blacks were less likely to undergo diagnostic evaluation (adjusted risk ratio = 0.88, 95% confidence interval = 0.83 to 0.93). Overall, among subjects with diagnostic colonoscopy (n = 10 424), there was no statistically significant difference by race in the prevalence of adenoma, advanced adenoma, advanced pathology in small adenomas (high-grade dysplasia or villous histology in adenomas <10 mm), or colorectal cancer. CONCLUSIONS: We observed a lower follow-up for screen-detected abnormalities among blacks when compared with whites but little difference in the yield of colorectal neoplasia. Health-care utilization may be playing more of a role in colorectal cancer racial disparity than biology.
BACKGROUND: It is unclear whether the disproportionately higher incidence and mortality from colorectal cancer among blacks compared with whites reflect differences in health-care utilization or colorectal cancer susceptibility. METHODS: A total of 60, 572 non-Hispanic white and black participants in the ongoing Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial underwent trial-sponsored screening flexible sigmoidoscopy (FSG) without biopsy at baseline in 10 geographically dispersed centers from November 1993 to July 2001. Subjects with polyps or mass lesions detected by FSG were referred to their physicians for diagnostic workup, the cost of which was not covered by PLCO. The records of follow-up evaluations were collected and reviewed. We used log binomial modeling with adjustment for age, education, sex, body mass index, smoking, family history of colorectal cancer, colon examination within previous 3 years, personal history of polyps, and screening center to examine whether utilization of diagnostic colonoscopy and yield of neoplasia differed by race. RESULTS: Among 57 561 whites and 3011 blacks who underwent FSG, 13,743 (23.9%) and 767 (25.5%) had abnormal examinations, respectively. A total of 9944 (72.4%) whites and 480 (62.6%) blacks had diagnostic colonoscopy within 1 year following the abnormal FSG screening. When compared with whites, blacks were less likely to undergo diagnostic evaluation (adjusted risk ratio = 0.88, 95% confidence interval = 0.83 to 0.93). Overall, among subjects with diagnostic colonoscopy (n = 10 424), there was no statistically significant difference by race in the prevalence of adenoma, advanced adenoma, advanced pathology in small adenomas (high-grade dysplasia or villous histology in adenomas <10 mm), or colorectal cancer. CONCLUSIONS: We observed a lower follow-up for screen-detected abnormalities among blacks when compared with whites but little difference in the yield of colorectal neoplasia. Health-care utilization may be playing more of a role in colorectal cancer racial disparity than biology.
Authors: P F Pinsky; A Miller; B S Kramer; T Church; D Reding; P Prorok; E Gelmann; R E Schoen; S Buys; R B Hayes; C D Berg Journal: Am J Epidemiol Date: 2007-01-22 Impact factor: 4.897
Authors: Laura-Mae Baldwin; Sharon A Dobie; Kevin Billingsley; Yong Cai; George E Wright; Jason A Dominitz; William Barlow; Joan L Warren; Stephen H Taplin Journal: J Natl Cancer Inst Date: 2005-08-17 Impact factor: 13.506
Authors: Jennifer S Haas; Craig C Earle; John E Orav; Phyllis Brawarsky; Bridget A Neville; David R Williams Journal: J Gen Intern Med Date: 2008-03-13 Impact factor: 5.128
Authors: Julia Gore Thornton; Arden M Morris; John Daryl Thornton; Christopher R Flowers; Timothy M McCashland Journal: J Natl Med Assoc Date: 2007-07 Impact factor: 1.798
Authors: Paul F Pinsky; Marvella Ford; Eduard Gamito; Darlene Higgins; Victoria Jenkins; Lois Lamerato; Sally Tenorio; Pamela M Marcus; John K Gohagan Journal: J Natl Med Assoc Date: 2008-03 Impact factor: 1.798
Authors: Cheryl J Pendergrass; Daniel L Edelstein; Linda M Hylind; Blaine T Phillips; Christine Iacobuzio-Donahue; Katharine Romans; Constance A Griffin; Marcia Cruz-Correa; Anne C Tersmette; G Johan A Offerhaus; Francis M Giardiello Journal: Clin Gastroenterol Hepatol Date: 2008-06-16 Impact factor: 11.382
Authors: Gwen Murphy; Susan S Devesa; Amanda J Cross; Peter D Inskip; Katherine A McGlynn; Michael B Cook Journal: Int J Cancer Date: 2010-05-25 Impact factor: 7.396
Authors: Sara E Erickson; Eduard E Vasilevskis; Michael W Kuzniewicz; Brian A Cason; Rondall K Lane; Mitzi L Dean; Deborah J Rennie; R Adams Dudley Journal: Crit Care Med Date: 2011-03 Impact factor: 7.598
Authors: Kelsey Lau-Min; Preeti Prakash; Eunji Jo; Aaron P Thrift; Susan Hilsenbeck; Benjamin L Musher Journal: Clin Colorectal Cancer Date: 2020-01-02 Impact factor: 4.481
Authors: Megan C Roberts; Rebecca A Ferrer; Katharine A Rendle; Sarah C Kobrin; Stephen H Taplin; Bradford W Hesse; William M P Klein Journal: Am J Prev Med Date: 2018-03-16 Impact factor: 5.043